Assessment of the physical dependence potential of difelikefalin: Randomized placebo‐controlled study in patients receiving hemodialysis

Abstract

Abstract Difelikefalin is a selective kappa opioid receptor agonist approved for treating moderate‐to‐severe pruritus in adults undergoing hemodialysis (HD). Difelikefalin is not a controlled substance under the Controlled Substances Act. This study assessed the potential for developing physical dependence on difelikefalin in patients undergoing HD. Eligible patients received open‐label difelikefalin after each dialysis session for 3 weeks before entering a 2‐week double‐blind phase, when they were randomized to either continue difelikefalin or to switch to receiving placebo. Signs of physical withdrawal were assessed using the Clinical Opiate Withdrawal Scale (COWS), several patient‐reported scales, and physiological measures. The primary end point was the between‐group difference in mean maximum COWS total scores during the double‐blind phase; the mean difference (placebo − difelikefalin) was compared against a predefined noninferiority limit (+4). Thirty‐five patients (57.1% male; 91.4% Black or African American; median [range] age 58 [28–77] years) were included, of which 30 were randomized (placebo, n = 14; difelikefalin, n = 16). The least squares mean difference in maximum COWS total scores was 0.52 (95% confidence interval [CI]: −0.56, 1.59). The upper CI limit (1.59) was below +4, indicating that patients who discontinued difelikefalin (placebo group) had similar withdrawal scores to patients who continued difelikefalin. Additional assessments supported the COWS results, showing no meaningful differences between groups in physiological measures or in patient‐reported measures of sleep or physical withdrawal. These results demonstrate that abruptly discontinuing chronic difelikefalin treatment in patients undergoing HD does not produce signs or symptoms of physical withdrawal.